# Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

> **NCT06536881** · NA · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- Early-stage Breast Cancer

## Interventions

- **BEHAVIORAL:** Fasting

## Key facts

- **NCT ID:** NCT06536881
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2028-08
- **Final completion:** 2029-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536881, "Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06536881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*